T-cell prolymphocytic leukemia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:86871C91.6
Who is this for?
Show terms as
8FDA treatments6Active trials37Specialists8Treatment centers4Financial resources

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

T-PLLT-cell chronic lymphocytic leukemia
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jun 2026Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center — PHASE1, PHASE2

TrialNOT YET RECRUITING
Apr 2026KESIMPTA: New indication approved
FDAcompleted
Feb 2026VENCLEXTA: New indication approved
FDAcompleted
Aug 2025KESIMPTA: New indication approved
FDAcompleted
May 2025Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jonsson Comprehensive Cancer Center — PHASE1, PHASE2

TrialRECRUITING
Apr 2025Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Anhui Provincial Hospital — NA

TrialRECRUITING
Apr 2024KESIMPTA: New indication approved
FDAcompleted
Feb 2024CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Zhu Xiaofan — NA

TrialRECRUITING
Jan 2024KESIMPTA: New indication approved
FDAcompleted
Jul 2023Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

University Health Network, Toronto — PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

8 available

Zydelig

idelalisib· Gilead Sciences, Inc.■ Boxed Warning
in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbiditi…

in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities

View Details →FDA Label ↗Patient Assistance ↗

BRUKINSA

zanubrutinib· BeOne Medicines USA, Inc.Orphan Drug

treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

View Details →FDA Label ↗

Rituxan SC

rituximab and recombinant human hyaluronidase· Genentech, Inc.Orphan Drug

Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide

View Details →Patient Assistance ↗

Bendeka

bendamustine for 50 ml admixture· Eagle Pharmaceuticals, Inc.Orphan Drug

Treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.

View Details →FDA Label ↗

ARZERRA

ofatumumab· Novartis Pharmaceuticals Corporation■ Boxed WarningOrphan Drug

Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine

View Details →FDA Label ↗

Treanda

Bendamustine hydrochloride· Cephalon, Inc.Orphan Drug

Treatment of patients with chronic lymphocytic leukemia

View Details →FDA Label ↗

Campath

alemtuzumab· Genzyme Corporation■ Boxed WarningOrphan Drug

The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.

View Details →FDA Label ↗

Fludara

Fludarabine phosphate· Berlex Laboratories, Inc.■ Boxed WarningOrphan Drug
View Details →FDA Label ↗

Clinical Trials

6 recruitingView all trials with filters →
Phase 14 trials
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Phase 1
Active
PI: Carlos Ramos, MD (Baylor College of Medicine) · Sites: Houston, Texas; Houston, Texas
View on ClinicalTrials.gov ↗I'm interested →
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Phase 1
Active
PI: Benjamin Tomlinson, MD (University Hospitals Cleveland Medical Center, Cas) · Sites: Cleveland, Ohio · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
FT819 in Subjects With B-cell Malignancies
Phase 1
Active
PI: Fate Trial Disclosure (Fate Therapeutics) · Sites: Birmingham, Alabama; Phoenix, Arizona +16 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
huCART19-IL18 in CD19+ Cancers
Phase 1
Active
PI: Jakub Svoboda, MD (University of Pennsylvania) · Sites: Philadelphia, Pennsylvania · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other1 trial
Observatory of Prolymphocytic Leukemia T
Actively Recruiting
PI: Kamel LARIBI, Dr (French Innovative Leukemia Organisation) · Sites: Le Mans · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 37View all specialists →
DM
David Maloney
Specialist
PI on 11 active trials
HM
Heng Mei
Specialist
PI on 4 active trials76 T-cell prolymphocytic leukemia publications
TK
Tapan M Kadia
Houston, Texas
Specialist

Rare Disease Specialist

PI on 9 active trials
JM
Jae Park, MD
Specialist
PI on 13 active trials
SM
Steven Horwitz, MD
Specialist
PI on 4 active trials
CD
Colleen Delaney
OLD GREENWICH, CT
Specialist
PI on 3 active trials
RN
Ryotaro Nakamura
Duarte, California
Specialist

Rare Disease Specialist

PI on 6 active trials
TM
Thomas C. Shea, MD
Specialist
PI on 4 active trials
FM
Filippo Milano
SEATTLE, WA
Specialist
PI on 7 active trials2 T-cell prolymphocytic leukemia publications
NR
Nancy Wells, DNSc, RN
Specialist
PI on 2 active trials
EM
Elizabeth Fox, MD
Specialist
PI on 5 active trials
NM
Nirali N Shah, M.D.
Specialist
PI on 7 active trials
JM
John C Reneau, MD
LAS VEGAS, NV
Specialist
PI on 1 active trial
CH
Chitra Hosing
HOUSTON, TX
Specialist
PI on 5 active trials
CP
Claudio G. Brunstein, MD, PhD
MINNEAPOLIS, MN
Specialist
PI on 6 active trials
CM
Colleen Annesley, MD
SEATTLE, WA
Specialist
PI on 5 active trials
FD
Fate Trial Disclosure
Specialist
PI on 9 active trials
MM
Margaret L. MacMillan, MD
Specialist
PI on 4 active trials
PP
Pierluigi Porcu
PHILADELPHIA, PA
Specialist
PI on 2 active trials
JM
James N Kochenderfer, M.D.
BETHESDA, MD
Specialist
PI on 6 active trials
AW
Ann Woolfrey
SEATTLE, WA
Specialist
PI on 5 active trials
TM
Tom R. Fitch, M.D.
GLENDALE, AZ
Specialist
PI on 1 active trial
TD
Tamila Kindwall-Keller, DO
Specialist
PI on 1 active trial19 T-cell prolymphocytic leukemia publications
PM
Paul Armistead, MD
CHAPEL HILL, NC
Specialist
PI on 1 active trial
CM
Chet Bohac, PharmD, MD, MSc
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

4 resources
Zydelig(idelalisib)— Gilead Sciences, Inc.
Rituxan SC(rituximab and recombinant human hyaluronidase)— Genentech, Inc.

GAZYVA

Genentech Inc., a member of the Roche Group

GAZYVA Patient Support (Genentech Access Solutions)

Patient Assistance
Manufacturer Program
Accepting applications

VENCLEXTA

AbbVie, Inc

VENCLEXTA Patient Support (AbbVie Patient Assistance)

Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to T-cell prolymphocytic leukemia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open T-cell prolymphocytic leukemiaForum →

No community posts yet. Be the first to share your experience with T-cell prolymphocytic leukemia.

Start the conversation →

Latest news about T-cell prolymphocytic leukemia

1 articles
Clinical trialUNITERAREApr 5, 2026
New Recruiting Trial: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, an…
See all news about T-cell prolymphocytic leukemia →

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about T-cell prolymphocytic leukemia

Are there clinical trials for T-cell prolymphocytic leukemia?

Yes — 6 recruiting clinical trials are currently listed for T-cell prolymphocytic leukemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat T-cell prolymphocytic leukemia?

25 specialists and care centers treating T-cell prolymphocytic leukemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for T-cell prolymphocytic leukemia?

5 patient support programs are currently tracked on UniteRare for T-cell prolymphocytic leukemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.